Smith & Nephew, plc (SNN - Free Report) recently announced the complete execution of the first-ever surgeries using its new JOURNEY II Unicompartmental Knee (UK) System.
This development is expected to provide a major impetus to the company’s Orthopaedics segment.
More on JOURNEY II UK System
The system integrates both an enhanced size range and lateral specific implant, which facilitates surgeons performing partial knee arthroplasty to maintain the shape, position and motion of a normal knee joint. The new JOURNEY II UK system has been developed to provide swifter recovery, better functionalityand improved patient outcomes than other unicompartmental options currently available in the market.
The system merges a simplistic surgical technique with an implant offering additional sizes for optimum coverage. The system is also cost-effective as it results in reduced OR footprint. Moreover, when used with the NAVI Handheld Robotics and VISIONAIRE Patient Matched Instrumentation, Smith & Nephew offers healthcare experts an unparalleled solution portfolio for partial knee replacements.
JOURNEY II UK leverages on the most superior technology from Smith & Nephew’s successful JOURNEY II platform as well as its ZUK Unicompartmental Knee.
Global commercial rollout of JOURNEY II UK is slated to begin in early 2020.
Per Mordor Intelligence, the knee replacement market is expected to witness a CAGR of nearly 3.7% during the forecast period of 2019-2024. Hence, this development comes at an ideal time.
Management is optimistic about the long-term opportunity for consistent use of technology and big data in combination with the company’s next generation robotics platform applied through the orthopaedics care cycle. Lately, the company has been investing in a few crucial product launches that are expected to strengthen its presence in the Orthopaedics market.
In November 2019, Smith & Nephew launched OR3O Dual Mobility System for use in primary and revision hip arthroplasty. This dual mobility implant uses a unique OXINIUM DH metal alloy and offers enhanced stability and an increased range of motion.
Over the past year, the stock has rallied 18.2% compared with the broader industry’s growth of 5.7%.
Zacks Rank & Stocks Worth a Look
Smith & Nephew currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , NuVasive, Inc (NUVA - Free Report) and ResMed (RMD - Free Report) . While ResMed sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>